Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Andrew J. Aguirre et al.|Cancer Discovery|2024Cited by 234
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Jingjing Jiang et al.|Nature|2024Cited by 175
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancerXinyuan Tong, Hongbin Ji, Ayushi S. Patel et al.|Cancer Cell|2024Cited by 115
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Andrew J. Aguirre, Rachel B. Keller et al.|Clinical Cancer Research|2023Cited by 46